Want to see RADX full AI Analyst Report?
RADX Stock Chart & Stats
$2.32
$0.11(3.10%)
At close: 4:00 PM EDT
$2.32
$0.11(3.10%)
Day’s Range― - ―
52-Week Range$1.00 - $16.25
Previous Close$3.44
Volume374.56K
Average Volume (3M)62.78K
Market Cap
$16.45M
Enterprise Value$45.00M
Total Cash (Recent Filing)$4.14M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.00
Next Earnings
Feb 26, 2027EPS Estimate
-1.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1404.00
Shares Outstanding15,702,943
10 Day Avg. Volume56,132
30 Day Avg. Volume62,785
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)2.90
Price to Sales (P/S)26.42
P/FCF Ratio0.00
Enterprise Value/Market Cap2.74
Enterprise Value/Revenue16.29
Enterprise Value/Gross Profit-42.22
Enterprise Value/Ebitda-0.65
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-2.89
Revenue Forecast (FY)$1.77M
Bulls Say, Bears Say
Bulls Say
RAD101 Clinical ProgressPositive interim Phase 2b data provide clinical validation for RAD101 and support progression toward a pivotal global Phase 3 study. If confirmed, the results could improve regulatory and partnering prospects while strengthening the company’s position in an area with no currently approved PET imaging products.
Debt-free Balance SheetHaving no reported debt reduces interest obligations, refinancing exposure, and creditor constraints while the company funds clinical development. This gives management greater flexibility in capital allocation, although the benefit is moderated by losses, declining equity, and the need for additional financing.
Strategic Clinical Manufacturing PartnershipA manufacturing and distribution partnership with Siemens Healthineers can support execution of the planned U.S. Phase 3 program and reduce commercialization infrastructure requirements. The relationship also adds validation and may improve Radiopharm’s ability to scale a successful RAD101 product.
Bears Say
Cash Depletion And Going-concern RiskRapid cash depletion materially limits the company’s ability to fund ongoing trials and corporate operations without further capital. The expected going-concern uncertainty signals that financing needs are not merely optional growth spending, increasing execution risk and weakening financial resilience over the next several quarters.
Deepening Losses And Weak RevenueThe combination of declining revenue and sharply widening losses shows that current commercial income is not covering the cost of clinical development. Persistent negative earnings reduce internal funding capacity and make the company increasingly dependent on successful trials, partnerships, or repeated external capital.
Equity Dilution From FinancingLarge new share issuance and additional equity-linked securities expand the capital base while increasing potential dilution for existing holders. Although the proceeds support clinical programs, reliance on repeated equity financing can raise the funding burden per share and constrain long-term shareholder economics.
Radiopharm Theranostics Limited Sponsored ADR News
RADX FAQ
What was Radiopharm Theranostics Limited Sponsored ADR’s price range in the past 12 months?
Radiopharm Theranostics Limited Sponsored ADR lowest stock price was $1.00 and its highest was $16.25 in the past 12 months.
What is Radiopharm Theranostics Limited Sponsored ADR’s market cap?
Radiopharm Theranostics Limited Sponsored ADR’s market cap is $16.45M.
When is Radiopharm Theranostics Limited Sponsored ADR’s upcoming earnings report date?
Radiopharm Theranostics Limited Sponsored ADR’s upcoming earnings report date is Feb 26, 2027 which is in 139 days.
How were Radiopharm Theranostics Limited Sponsored ADR’s earnings last quarter?
Radiopharm Theranostics Limited Sponsored ADR released its earnings results on Aug 28, 2026. The company reported -$2.109 earnings per share for the quarter, beating the consensus estimate of -$2.556 by $0.447.
Is Radiopharm Theranostics Limited Sponsored ADR overvalued?
According to Wall Street analysts Radiopharm Theranostics Limited Sponsored ADR’s price is currently Overvalued.
Does Radiopharm Theranostics Limited Sponsored ADR pay dividends?
Radiopharm Theranostics Limited Sponsored ADR does not currently pay dividends.
What is Radiopharm Theranostics Limited Sponsored ADR’s EPS estimate?
Radiopharm Theranostics Limited Sponsored ADR’s EPS estimate is -1.05.
How many shares outstanding does Radiopharm Theranostics Limited Sponsored ADR have?
Radiopharm Theranostics Limited Sponsored ADR has 15,702,943 shares outstanding.
What happened to Radiopharm Theranostics Limited Sponsored ADR’s price movement after its last earnings report?
Radiopharm Theranostics Limited Sponsored ADR reported an EPS of -$2.109 in its last earnings report, beating expectations of -$2.556. Following the earnings report the stock price went up 6.637%.
Which hedge fund is a major shareholder of Radiopharm Theranostics Limited Sponsored ADR?
Currently, no hedge funds are holding shares in RADX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Radiopharm Theranostics Limited Sponsored ADR
Radiopharm Theranostics Limited, an Australian company established in Carlton in 2021, specializes in the research and development of cutting-edge radiopharmaceutical treatments. Their mission is to address critical gaps in healthcare by creating products for both diagnostic imaging and therapeutic intervention across a spectrum of challenging medical conditions. The company's diverse pipeline features: RAD 204, designed to target PD-L1 for non-small cell lung cancer; RAD 202, aimed at HER2 for breast cancer and other solid tumor types; and two avß6 integrin-targeting agents, RAD 301 (a diagnostic tool for pancreatic ductal adenocarcinoma) and RAD 302 (a therapeutic agent for various cancers). Other significant developments include RAD 101 and RAD 102 for brain metastases, RAD 402 for advanced prostate cancer, and RV01 for multiple solid tumors. To accelerate the clinical progression of its radiopharmaceutical assets, Radiopharm Theranostics maintains a strategic partnership with Lantheus Holdings, Inc.
Technical Analysis
Serina Therapeutics
―
Celularity
―
―
Acrivon Therapeutics, Inc.
―
Telomir Pharmaceuticals, Inc.
―